Market Access News | pharmaphorum

News

CHMP backs Roche's Enspryng for rare nerve disease NMOSD

Roche's Enspryng has been recommended for approval in the EU for treating neuromyelitis optica spectrum disorder (NMOSD), extending the treatment options for people with the life-threatenin

News

Calliditas eyes 2022 approval in EU for rare kidney disease ...

Calliditas Therapeutics is on course to launch its first product, Nefecon for rare disease primary IgA nephropathy (IgAN), in the first half of 2022 after getting the green light for an acc

News

FDA pens stinging report on Emergent COVID vaccine plant

Emergent BioSolutions' difficult month has been made worse by an FDA report into its facility in Baltimore, which has been blamed for the wastage of millions of doses of Johnson & Johns

News

Hikma shares rally after US launch of Advair generic resumes

Shares in Hikma have rallied as it resumed the launch of its generic Advair Diskus in the US, after clearing up a final piece of bureaucracy with the FDA.

News

EU safety regulators clear J&J COVID shot despite tiny clot ...

The benefits of Johnson & Johnson’s COVID-19 vaccine outweigh a tiny risk of unusual blood clots forming, Europe’s drugs regulator has said.

News

Enhertu cleared for NHS use via Cancer Drugs Fund

NICE has recommended the use of AstraZeneca and Daiichi Sankyo's Enhertu in draft guidance, the first time the drug has been commissioned in any European country.

CHMP backs Roche's Enspryng for rare nerve disease NMOSD

Calliditas eyes 2022 approval in EU for rare kidney disease ...

FDA pens stinging report on Emergent COVID vaccine plant

Hikma shares rally after US launch of Advair generic resumes

EU safety regulators clear J&J COVID shot despite tiny clot ...

Enhertu cleared for NHS use via Cancer Drugs Fund

Andexxa reaches the end of the line in the US

How to meet your physicians where they are online

News

Editor's Picks